JMJD7

Summary

JMJD7 (jumonji domain containing 7, HGNC:34397) is a protein-coding gene on chromosome 15q15.1, encoding Bifunctional peptidase and (3S)-lysyl hydroxylase JMJD7 (P0C870). Bifunctional enzyme that acts both as an endopeptidase and 2-oxoglutarate-dependent monooxygenase.

This gene encodes a highly conserved protein with a JmjC domain, which are part of the cupin metalloenzyme superfamily. JmjC proteins may function as 2-oxoglutarate-Fe(II)-dependent dioxygenases. Most tissues also express read-through transcripts from this gene into the downstream phospholipase A2, group IVB (cytosolic) gene, some of which may encode fusion proteins combining the N-terminus of this protein with the phospholipase A2, group IVB protein.

Source: NCBI Gene 100137047 — RefSeq curated summary.

At a glance

• GWAS associations: 5
• Clinical variants (ClinVar): 31 total
• Druggable target: yes — 2 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_001114632

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:34397
Approved symbol	JMJD7
Name	jumonji domain containing 7
Location	15q15.1
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000243789
Ensembl biotype	protein_coding
OMIM	621306
Entrez	100137047

Gene structure

Transcript identifiers

Ensembl transcripts: 8 — 5 protein_coding, 2 protein_coding_CDS_not_defined, 1 retained_intron

ENST00000397299, ENST00000405106, ENST00000408047, ENST00000431823, ENST00000478178, ENST00000562035, ENST00000864345, ENST00000922178

RefSeq mRNA: 1 — MANE Select: NM_001114632 NM_001114632

CCDS: CCDS45240

Canonical transcript exons

ENST00000397299 — 8 exons

Exon	Start	End
ENSE00001550778	41837068	41837581
ENSE00003481982	41836148	41836243
ENSE00003584292	41828092	41828188
ENSE00003596324	41834970	41835223
ENSE00003617077	41834740	41834893
ENSE00003642219	41835588	41835644
ENSE00003664778	41836781	41836940
ENSE00003784809	41836475	41836551

Expression profiles

Bgee: expression breadth ubiquitous, 134 present calls, max score 93.82.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 10.0823 / max 136.2197, expressed in 1763 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
146214	10.0823	1763

Top tissues by expression

134 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
lower esophagus mucosa	UBERON:0035834	93.82	gold quality
esophagus mucosa	UBERON:0002469	91.13	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	90.53	gold quality
skin of abdomen	UBERON:0001416	90.45	gold quality
zone of skin	UBERON:0000014	89.98	gold quality
right hemisphere of cerebellum	UBERON:0014890	89.97	gold quality
cerebellum	UBERON:0002037	89.77	gold quality
cerebellar hemisphere	UBERON:0002245	89.75	gold quality
cerebellar cortex	UBERON:0002129	89.72	gold quality
skin of leg	UBERON:0001511	89.67	gold quality
granulocyte	CL:0000094	88.73	gold quality
saliva-secreting gland	UBERON:0001044	87.49	gold quality
apex of heart	UBERON:0002098	87.49	gold quality
minor salivary gland	UBERON:0001830	87.21	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	86.71	gold quality
vagina	UBERON:0000996	86.12	gold quality
tonsil	UBERON:0002372	85.64	gold quality
esophagus	UBERON:0001043	85.40	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	85.31	gold quality
right lobe of thyroid gland	UBERON:0001119	84.70	gold quality
body of pancreas	UBERON:0001150	84.68	gold quality
thyroid gland	UBERON:0002046	84.01	gold quality
left lobe of thyroid gland	UBERON:0001120	84.00	gold quality
heart left ventricle	UBERON:0002084	83.55	gold quality
body of stomach	UBERON:0001161	83.45	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	83.16	gold quality
substantia nigra	UBERON:0002038	82.99	gold quality
prostate gland	UBERON:0002367	82.83	gold quality
blood	UBERON:0000178	82.57	gold quality
prefrontal cortex	UBERON:0000451	82.56	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-GEOD-100618	yes	719.45
E-ANND-3	no	1.01

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

9 targeting JMJD7, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-12123	99.52	71.79	2990
HSA-MIR-3688-5P	99.12	69.67	1091
HSA-MIR-4272	98.76	68.74	1810
HSA-MIR-767-3P	98.61	67.69	1192
HSA-MIR-3661	97.83	67.30	705
HSA-MIR-6782-3P	97.60	67.75	931
HSA-MIR-4695-3P	96.71	67.21	836
HSA-MIR-500B-3P	96.49	65.40	1087
HSA-MIR-644A	96.02	66.52	786

Literature-anchored findings (GeneRIF, showing 3)

• JMJD7-PLA2G4B may serve as an important therapeutic target and prognostic marker for head and neck squamous cell carcinoma development and progression. (PMID:28030848)
• The protease activities of JMJD5 and JMJD7 represent a mechanism for removal of histone tails bearing methylated arginine residues and define a potential mechanism of transcription regulation. (PMID:28847961)
• Substrate selectivity and inhibition of the human lysyl hydroxylase JMJD7. (PMID:39276004)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	jmjd7	ENSDARG00000035546
mus_musculus	Jmjd7	ENSMUSG00000098789
rattus_norvegicus	Jmjd7	ENSRNOG00000050072
drosophila_melanogaster	JMJD7	FBGN0036366

Paralogs (4): KDM8 (ENSG00000155666), TYW5 (ENSG00000162971), HIF1AN (ENSG00000166135), HSPBAP1 (ENSG00000169087)

Protein

Protein identifiers

Bifunctional peptidase and (3S)-lysyl hydroxylase JMJD7 — P0C870 (reviewed: P0C870)

Alternative names: JmjC domain-containing protein 7, Jumonji domain-containing protein 7, L-lysine (3S)-hydroxylase JMJD7

All UniProt accessions (3): P0C870, B5MC20, C9K0I3

UniProt curated annotations — full annotation on UniProt →

Function. Bifunctional enzyme that acts both as an endopeptidase and 2-oxoglutarate-dependent monooxygenase. Endopeptidase that cleaves histones N-terminal tails at the carboxyl side of methylated arginine or lysine residues, to generate ’tailless nucleosomes’, which may trigger transcription elongation. Preferentially recognizes and cleaves monomethylated and dimethylated arginine residues of histones H2, H3 and H4. After initial cleavage, continues to digest histones tails via its aminopeptidase activity. Additionally, may play a role in protein biosynthesis by modifying the translation machinery. Acts as a Fe(2+) and 2-oxoglutarate-dependent monooxygenase, catalyzing (S)-stereospecific hydroxylation at C-3 of ‘Lys-22’ of DRG1 and ‘Lys-21’ of DRG2 translation factors (TRAFAC), promoting their interaction with ribonucleic acids (RNA).

Subunit / interactions. Homodimer; disulfide-linked. Interacts with DRG1 and DRG2.

Subcellular location. Nucleus. Cytoplasm.

RefSeq proteins (1): NP_001108104* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR003347	JmjC_dom	Domain
IPR014710	RmlC-like_jellyroll	Homologous_superfamily
IPR041667	Cupin_8	Domain

Pfam: PF13621

Enzyme classification (BRENDA):

• EC 1.14.11.27 — [histone H3]-dimethyl-L-lysine36 demethylase (BRENDA: 7 organisms, 38 substrates, 0 inhibitors, 0 Km, 0 kcat entries)
• EC 1.14.11.63 — peptidyl-lysine (3S)-dioxygenase (BRENDA: 3 organisms, 5 substrates, 7 inhibitors, 0 Km, 0 kcat entries)

Catalyzed reactions (Rhea), 1 shown:

• L-lysyl-[protein] + 2-oxoglutarate + O2 = (3S)-3-hydroxy-L-lysyl-[protein] + succinate + CO2 (RHEA:57152)

UniProt features (41 total): strand 16, helix 11, mutagenesis site 4, binding site 3, turn 2, sequence variant 2, chain 1, domain 1, disulfide bond 1

Structure

Experimental structures (PDB)

2 structures.

PDB	Method	Resolution (Å)
5NFO	X-RAY DIFFRACTION	2.17
5NFN	X-RAY DIFFRACTION	2.98

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P0C870-F1	97.89	0.98

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (3): 178; 180; 277

Disulfide bonds (1): 47

Mutagenesis-validated functional residues (4):

Position	Phenotype
180	loss of peptidase activity toward methylated histones and reduced anchorage-independent growth of transformed cells; whe
277	loss of peptidase activity toward methylated histones and reduced anchorage-independent growth of transformed cells; whe
47	impairs homodimer formation.
178	loss of peptidase activity toward methylated histones and reduced anchorage-independent growth of transformed cells; whe

Function

Pathways and Gene Ontology

Reactome pathways

4 pathways

ID	Pathway
R-HSA-9629569	Protein hydroxylation
R-HSA-163841	Gamma carboxylation, hypusinylation, hydroxylation, and arylsulfatase activation
R-HSA-392499	Metabolism of proteins
R-HSA-597592	Post-translational protein modification

MSigDB gene sets: 30 (showing top): GOMF_OXIDOREDUCTASE_ACTIVITY_ACTING_ON_PAIRED_DONORS_WITH_INCORPORATION_OR_REDUCTION_OF_MOLECULAR_OXYGEN, GOBP_PEPTIDYL_LYSINE_MODIFICATION, CADWELL_ATG16L1_TARGETS_DN, GOBP_PROTEIN_HYDROXYLATION, GOBP_PROTEOLYSIS, GOMF_PEPTIDASE_ACTIVITY, GOMF_AMINOPEPTIDASE_ACTIVITY, GOMF_DIOXYGENASE_ACTIVITY, GOMF_EXOPEPTIDASE_ACTIVITY, REACTOME_POST_TRANSLATIONAL_PROTEIN_MODIFICATION, GOMF_MONOOXYGENASE_ACTIVITY, GOBP_PEPTIDYL_LYSINE_HYDROXYLATION, REACTOME_GAMMA_CARBOXYLATION_HYPUSINYLATION_HYDROXYLATION_AND_ARYLSULFATASE_ACTIVATION, FEV_TARGET_GENES, FOXD2_TARGET_GENES

GO Biological Process (2): proteolysis (GO:0006508), protein hydroxylation (GO:0018126)

GO Molecular Function (10): endopeptidase activity (GO:0004175), aminopeptidase activity (GO:0004177), monooxygenase activity (GO:0004497), 2-oxoglutarate-dependent dioxygenase activity (GO:0016706), metal ion binding (GO:0046872), peptidyl-lysine 3-dioxygenase activity (GO:0106155), protein binding (GO:0005515), peptidase activity (GO:0008233), oxidoreductase activity (GO:0016491), hydrolase activity (GO:0016787)

GO Cellular Component (3): nucleus (GO:0005634), cytoplasm (GO:0005737), cytosol (GO:0005829)

Reactome top-level categories

Rollup of top-3 pathways:

Category	Pathways
Gamma carboxylation, hypusinylation, hydroxylation, and arylsulfatase activation	1
Post-translational protein modification	1
Metabolism of proteins	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
catalytic activity, acting on a protein	2
catalytic activity	2
cellular anatomical structure	2
protein metabolic process	1
protein modification process	1
peptidase activity	1
exopeptidase activity	1
oxidoreductase activity	1
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen	1
dioxygenase activity	1
cation binding	1
2-oxoglutarate-dependent dioxygenase activity	1
binding	1
hydrolase activity	1
intracellular membrane-bounded organelle	1
intracellular anatomical structure	1
cytoplasm	1

Protein interactions and networks

STRING

236 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
JMJD7	RIOX2	Q8IUF8	513
JMJD7	DRG2	P55039	507
JMJD7	JMJD4	Q9H9V9	506
JMJD7	U3KPZ7	U3KPZ7	445
JMJD7	HR	O43593	444
JMJD7	RIOX1	Q9H6W3	420
JMJD7	ZC3H15	Q8WU90	419
JMJD7	RWDD1	Q9H446	412
JMJD7	PLA2G4B	P0C869	411
JMJD7	PRMT9	Q6P2P2	352
JMJD7	JMJD8	Q96S16	348
JMJD7	PLA2G3	Q9NZ20	326
JMJD7	PHF2	O75151	299
JMJD7	KDM4E	B2RXH2	275
JMJD7	JMJD6	Q6NYC1	273

IntAct

64 interactions, top by confidence:

A	B	Type	Score
JMJD7	VAC14	psi-mi:“MI:0915”(physical association)	0.560
VAC14	JMJD7	psi-mi:“MI:0915”(physical association)	0.560
JMJD7	OXER1	psi-mi:“MI:0915”(physical association)	0.560
SNRPC	JMJD7	psi-mi:“MI:0915”(physical association)	0.560
JMJD7	SAMD11	psi-mi:“MI:0915”(physical association)	0.560
JMJD7	POM121	psi-mi:“MI:0915”(physical association)	0.560
JMJD7	FOXI1	psi-mi:“MI:0915”(physical association)	0.560
GCM2	JMJD7	psi-mi:“MI:0915”(physical association)	0.560
JMJD7	UBAP2	psi-mi:“MI:0915”(physical association)	0.560
JMJD7	DRG2	psi-mi:“MI:0915”(physical association)	0.560
HGS	JMJD7	psi-mi:“MI:0915”(physical association)	0.560
POGZ	JMJD7	psi-mi:“MI:0915”(physical association)	0.560
JMJD7	CASP6	psi-mi:“MI:0915”(physical association)	0.560
JMJD7	HSPB1	psi-mi:“MI:0915”(physical association)	0.560
JMJD7	LAMP2	psi-mi:“MI:0915”(physical association)	0.560
JMJD7	RAN	psi-mi:“MI:0915”(physical association)	0.560
JMJD7	WFS1	psi-mi:“MI:0915”(physical association)	0.560
JMJD7	KIF1B	psi-mi:“MI:0915”(physical association)	0.560
JMJD7	SH3GLB1	psi-mi:“MI:0915”(physical association)	0.560
JMJD7	PRPF40A	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (21): JMJD7 (Two-hybrid), JMJD7 (Two-hybrid), JMJD7 (Two-hybrid), JMJD7 (Two-hybrid), JMJD7 (Two-hybrid), JMJD7 (Two-hybrid), JMJD7 (Two-hybrid), JMJD7 (Two-hybrid), JMJD7 (Two-hybrid), JMJD7 (Two-hybrid), JMJD7 (Two-hybrid), JMJD7 (Affinity Capture-MS), CCT2 (Affinity Capture-MS), CCT7 (Affinity Capture-MS), CCT8 (Affinity Capture-MS)

ESM2 similar proteins: A2AV36, A2RSX7, A2RUC4, A4IHY0, A6QQV6, A8E534, B2GUS6, B5XF11, E1C7T6, E9PYK3, F1RET2, P0C870, P0C872, P47823, P59723, P83006, Q08BV2, Q08BY5, Q0VCA8, Q0WVR4, Q3UDE2, Q3V3E1, Q58CU3, Q5BKC6, Q5EA24, Q5R673, Q5U4E8, Q5ZHV5, Q5ZIB9, Q66KI9, Q67XX3, Q67ZB6, Q6AXL5, Q6PCI6, Q7T0X7, Q7TMC8, Q8BFT6, Q8BGG7, Q8BK58, Q8BLR9

Diamond homologs: A2RSX7, P0C870, P0C872, Q0WVR4, Q54CS7, Q9VU77, O94606, Q8BLR9, Q9NWT6, Q67XX3, F4K2M8

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

31 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	21
Likely benign	5
Benign	4

Top pathogenic / likely-pathogenic (0)

SpliceAI

1973 predictions. Top by Δscore:

Variant	Effect	Δscore
15:41828186:GGG:G	donor_gain	1.0000
15:41828186:GGGGT:G	donor_loss	1.0000
15:41828187:GG:G	donor_gain	1.0000
15:41828187:GGG:G	donor_gain	1.0000
15:41828188:GG:G	donor_gain	1.0000
15:41828188:GGTG:G	donor_loss	1.0000
15:41828189:G:GG	donor_gain	1.0000
15:41828189:GT:G	donor_loss	1.0000
15:41828189:GTGA:G	donor_loss	1.0000
15:41828190:T:A	donor_loss	1.0000
15:41834870:G:GT	donor_gain	1.0000
15:41835222:GG:G	donor_gain	1.0000
15:41835223:GG:G	donor_gain	1.0000
15:41835224:G:GG	donor_gain	1.0000
15:41835224:GTGA:G	donor_loss	1.0000
15:41835645:G:GG	donor_gain	1.0000
15:41836142:T:A	acceptor_gain	1.0000
15:41836241:ATGGT:A	donor_loss	1.0000
15:41836242:TGG:T	donor_loss	1.0000
15:41836244:GTAG:G	donor_loss	1.0000
15:41836245:T:A	donor_loss	1.0000
15:41836465:T:A	acceptor_gain	1.0000
15:41836466:G:A	acceptor_gain	1.0000
15:41837066:A:AG	acceptor_gain	1.0000
15:41837067:G:GG	acceptor_gain	1.0000
15:41837067:GTGA:G	acceptor_gain	1.0000
15:41828185:AGGG:A	donor_gain	0.9900
15:41828186:GGGG:G	donor_gain	0.9900
15:41834736:TCAG:T	acceptor_gain	0.9900
15:41834738:A:AG	acceptor_gain	0.9900

AlphaMissense

2046 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
15:41836150:C:G	H178D	0.998
15:41836157:A:C	D180A	0.998
15:41836157:A:T	D180V	0.998
15:41836907:C:G	H277D	0.998
15:41835046:T:C	F99L	0.997
15:41835048:C:A	F99L	0.997
15:41835048:C:G	F99L	0.997
15:41835610:C:A	N165K	0.997
15:41835610:C:G	N165K	0.997
15:41835614:T:A	W167R	0.997
15:41835614:T:C	W167R	0.997
15:41837072:T:A	N289K	0.997
15:41837072:T:G	N289K	0.997
15:41836156:G:C	D180H	0.996
15:41836157:A:G	D180G	0.996
15:41836158:C:A	D180E	0.996
15:41836158:C:G	D180E	0.996
15:41836170:C:A	N184K	0.996
15:41836170:C:G	N184K	0.996
15:41836787:T:A	W237R	0.996
15:41836787:T:C	W237R	0.996
15:41834874:T:A	W67R	0.995
15:41834874:T:C	W67R	0.995
15:41835047:T:C	F99S	0.995
15:41835639:C:T	T175I	0.995
15:41836904:T:C	F276L	0.995
15:41836906:C:A	F276L	0.995
15:41836906:C:G	F276L	0.995
15:41836150:C:A	H178N	0.994
15:41836166:A:T	E183V	0.994

dbSNP variants (sampled 300 via entrez): RS1000072675 (15:41829698 A>G), RS1000127284 (15:41833547 C>T), RS1000783038 (15:41834250 T>G), RS1000880083 (15:41830687 C>G,T), RS1000926219 (15:41835949 C>T), RS1000956142 (15:41826619 G>A), RS1001121060 (15:41835328 C>G,T), RS1001351875 (15:41834567 G>A), RS1001561295 (15:41830926 A>G), RS1001904668 (15:41828579 A>G), RS1001973957 (15:41827451 C>T), RS1002021797 (15:41831889 A>G), RS1002156036 (15:41838073 C>T), RS1002539629 (15:41832016 C>T), RS1002774872 (15:41836035 C>T)

Disease associations

OMIM: gene MIM:621306 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

5 associations (top):

Study	Trait	p-value
GCST90020024_483	A body shape index	3.000000e-09
GCST90020025_142	Waist-to-hip ratio adjusted for BMI	2.000000e-08
GCST90020025_450	Waist-to-hip ratio adjusted for BMI	1.000000e-09
GCST90020027_628	Waist-hip index	1.000000e-09
GCST90020027_629	Waist-hip index	1.000000e-08

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0007789	BMI-adjusted waist circumference
EFO:0007788	BMI-adjusted waist-hip ratio

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL4879430 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

2 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 1,281 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL197194	VIDOFLUDIMUS	3	808
CHEMBL3982723	DAROVASERTIB	2	473

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

4 potent at pChembl≥5 of 9 total, top 4 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
5.93	Kd	1180	nM	CHEMBL4846929
5.42	IC50	3800	nM	CHEMBL4846929
5.18	IC50	6620	nM	CHEMBL4846929
5.14	IC50	7160	nM	VIDOFLUDIMUS

PubChem BioAssay actives

4 with measured affinity, of 11 total; 2 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
(5-nitroquinolin-8-yl) 2,4-dichlorobenzoate	1763997: Binding affinity to N-terminal His-tagged human JMJD7 (1 to 316 residues) expressed in Escherichia coli BL21 (DE3) measured by MST assay	kd	1.1800	uM
2-[[2-fluoro-4-(3-methoxyphenyl)phenyl]carbamoyl]cyclopentene-1-carboxylic acid	1763996: Inhibition of N-terminal His-tagged human JMJD7 (1 to 316 residues) expressed in Escherichia coli BL21 (DE3) luciferase based succinate-gloTM JmjC demethylase/hydroxylase assay	ic50	7.1600	uM

CTD chemical–gene interactions

12 total (human), top 12 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
gallium arsenide	decreases expression	1
CGP 52608	affects binding, increases reaction	1
jinfukang	affects cotreatment, increases expression	1
Sunitinib	decreases expression	1
Arsenicals	increases expression	1
Benzo(a)pyrene	increases methylation	1
Cisplatin	affects cotreatment, increases expression	1
Estradiol	affects cotreatment, decreases expression	1
Smoke	decreases expression	1
Tobacco Smoke Pollution	increases expression	1
Urethane	decreases expression	1
Valproic Acid	increases methylation	1

ChEMBL screening assays

5 unique, capped per target: 5 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4822994	Binding	Inhibition of N-terminal His-tagged human JMJD7 (1 to 316 residues) expressed in Escherichia coli BL21 (DE3) luciferase based succinate-gloTM JmjC demethylase/hydroxylase assay	Discovery of JMJD7 inhibitors with the aid of virtual screening and bioactivity evaluation. — Bioorg Med Chem Lett

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.